Cibus, Inc.
NASDAQ:CBUS · NASDAQ Capital Market
-$0.02 today
Vol 0.11M · Avg 0.52M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CBUS · Revenue to Net Income
Key Ratios
Analysis
$4.3M of revenue converted into -$101.4M of net income for the selected period. Gross margin is 82.2% and net margin is -2692.4%, showing how much revenue survives after costs and taxes. EPS is $-1.77, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M -14.6% | $4.3M +134.6% | $1.8M +1057.3% | $157.0K -99.4% | $26.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $5.9M | $0 -100.0% | $395.0K -74.3% | $1.5M -94.6% | $28.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$2.3M -153.6% | $4.3M +199.7% | $1.4M +203.3% | -$1.4M +46.4% | -$2.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | -62.8% -162.8pp | 100.0% +21.7pp | 78.3% +955.3pp | -877.1% -867.2pp | -9.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $44.2M -12.4% | $50.4M +19.0% | $42.4M +266.7% | $11.6M +1.9% | $11.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $26.9M -12.6% | $30.8M +6.5% | $28.9M +206.3% | $9.4M -38.6% | $15.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $65.2M -75.2% | $262.7M -18.0% | $320.3M +1425.8% | $21.0M -21.6% | $26.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.9M -13.6% | $6.9M +46.2% | $4.7M +205.9% | $1.5M -34.4% | $2.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$90.8M +62.4% | -$241.6M +23.2% | -$314.6M -1968.3% | -$15.2M +40.2% | -$25.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -2494.3% +3175.2pp | -5669.5% +11643.9pp | -17313.4% -7625.5pp | -9687.9% -9590.0pp | -97.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$67.5M +73.9% | -$258.4M +19.0% | -$318.9M -1325.5% | -$22.4M +23.7% | -$29.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1853.9% +4208.9pp | -6062.8% +11487.2pp | -17550.0% -3301.6pp | -14248.4% -14135.5pp | -112.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $438.0K -30.6% | $631.0K +19.7% | $527.0K +778.3% | $60.0K +252.9% | $17.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $35.5M +3.8% | $34.2M +81.0% | $18.9M +21614.9% | $87.0K -93.9% | $1.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$64.7M -166.4% | -$24.3M -29.5% | -$18.8M -442.4% | $5.5M +4019.5% | $133.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$132.2M +53.2% | -$282.7M +16.3% | -$337.6M -1899.0% | -$16.9M +42.2% | -$29.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -3632.1% +3000.6pp | -6632.7% +11949.8pp | -18582.4% -7823.8pp | -10758.6% -10646.2pp | -112.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $29.0K +0.0% | $29.0K +825.0% | -$4.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$127.1M +49.4% | -$251.4M +6.1% | -$267.6M -1484.4% | -$16.9M +42.2% | -$29.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -3492.3% +2406.1pp | -5898.4% +8830.7pp | -14729.1% -3970.5pp | -10758.6% -10646.2pp | -112.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +74.3% | -$11 +58.3% | -$26 -88769.9% | -$0 +42.2% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +74.3% | -$11 +58.3% | -$26 -88769.9% | -$0 +42.2% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $457.6M +1870.4% | $23.2M +125.1% | $10.3M -98.2% | $578.5M +0.0% | $578.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $457.6M +1870.4% | $23.2M +125.1% | $10.3M -98.2% | $578.5M +0.0% | $578.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$155.81M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Repare Therapeutics Inc.
RPTX
$114.24M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
MediciNova, Inc.
NASDAQ:MNOV
$60.54M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CBUS generate?
Cibus, Inc. (CBUS) reported $3.64M of revenue in fiscal 2025.
Is CBUS profitable?
Cibus, Inc. (CBUS) reported -$127,085,000.00 of net income, with a net margin of -3492.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.